Results 151 to 160 of about 1,641 (192)
Profile of a Novel Anionic Fluoroquinolone—Delafloxacin [PDF]
Clinical Infectious Diseases, 2019 Fluoroquinolones have been in clinical use for over 50 years with significant efficacy. However, increasing resistance and emergence of some marked adverse events have limited their usage. The most recently approved class member, delafloxacin, is the only available anionic (non-zwitterionic) fluoroquinolone.
Paul M Tulkens +2 more
exaly +4 more sources
Clinical review of delafloxacin: a novel anionic fluoroquinolone [PDF]
Journal of Antimicrobial Chemotherapy, 2018 Delafloxacin is a novel anionic fluoroquinolone (FQ) approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by a number of Gram-positive and Gram-negative organisms including MRSA and Pseudomonas aeruginosa. The unique chemical structure of delafloxacin renders it a weak acid and results in increased potency in ...
Bryan T Mogle +2 more
exaly +3 more sources
Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties [PDF]
Infectious Diseases and Therapy, 2018 Delafloxacin (formerly WQ-3034, ABT492, RX-3341) is a novel fluoroquinolone chemically distinct from currently marketed fluoroquinolones with the absence of a protonatable substituent conferring a weakly acidic character to the molecule.
Susan L Davis
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Delafloxacin: A Review in Community-Acquired Pneumonia
Drugs, 2022Delafloxacin (BAXDELA® in the USA; Quofenix® in the EU) is an anionic fluoroquinolone antibacterial that is approved for the treatment of community-acquired pneumonia (CAP) and acute bacterial skin and skin structure infections in adults. Delafloxacin demonstrated in vitro activity against Gram-positive and Gram-negative pathogens, including drug ...
Arnold Lee, Yvette N. Lamb, Matt Shirley
openaire +2 more sources
Early Clinical Experience with Delafloxacin: A Case Series
The American Journal of the Medical Sciences, 2022The most recently approved fluoroquinolone for use in the US and Europe, delafloxacin (DLX) provides broad-spectrum coverage, improved side effect profile, and excellent potency. Currently approved for the treatment of acute bacterial skin infections and community-acquired pneumonia, DLX may be useful in the treatment of other infections given the ...
J Patrik, Hornak, David, Reynoso
openaire +2 more sources